IGF-1 DES

How does IGF-1 DES work?

IGF-1 DES (des(1-3)IGF-1) is a truncated IGF-1 analogue missing the N-terminal tripeptide Gly-Pro-Glu. Removing this tripeptide — especially the Glu3 residue — sharply lowers the peptide's affinity for the IGF-binding proteins (IGFBPs) that normally sequester circulating IGF-1. Because it escapes IGFBP sequestration, more free peptide reaches the type-1 IGF receptor. This is an AVAILABILITY effect, not stronger receptor binding: des(1-3)IGF-1 binds the IGF-1 receptor equal to or slightly worse than intact IGF-1.

1. N-terminal truncation [1]. IGF-1 DES lacks the first three N-terminal amino acids (Gly-Pro-Glu) of the 70-residue IGF-1 sequence, leaving a 67-amino-acid peptide. The deletion of Glu3 in particular is what disrupts high-affinity IGFBP binding.
2. IGFBP evasion is the core mechanism [2]. IGF-binding proteins normally bind and sequester the great majority of circulating IGF-1 and IGF-2, blunting their activity. In the defining experiment, IGFBPs suppressed IGF-1 and IGF-2 activity but had essentially NO effect on des(1-3)IGF-1 — establishing that the derivative works by escaping IGFBP sequestration.
3. Greater availability, not greater affinity [1][4]. Because more free peptide reaches the receptor, des(1-3)IGF-1 shows roughly 7–10x greater potency in cell assays and about 2.5x in vivo in rats. Yet in direct binding studies it binds the IGF-1 receptor equal to or slightly WORSE than intact IGF-1 — the potency is an availability effect, full stop.
4. Downstream signaling is conventional. Once bound to the type-1 IGF receptor, the resulting signaling (PI3K/Akt and MAPK pathways driving protein synthesis and anti-catabolic effects) is the same as for intact IGF-1. IGF-1 DES does not introduce a novel signaling route — it simply delivers more agonist to the same receptor.
5. Shorter systemic residence [2]. Escaping IGFBP binding also removes the carrier reservoir that prolongs intact IGF-1's circulating half-life. IGFBP-evasion therefore tends to SHORTEN systemic residence relative to IGFBP-bound IGF-1 — one reason free IGF peptides are understood to clear rapidly.

What is IGF-1 DES used for?

IGF-1 DES has been characterized almost exclusively in preclinical work: cell-culture potency and receptor-binding assays, and rodent anabolism studies from the late 1980s and early 1990s. There are no controlled human efficacy or safety trials. Everything below is animal or cell data — stated plainly so it is not mistaken for evidence of human benefit.

1. Potency and receptor-binding characterization [1]. Ballard 1987 established that des(1-3)IGF-1 was ~7x more potent than intact IGF-1 in a protein-synthesis bioassay, and that this potency was not explained by tighter IGF-1 receptor binding.
2. The IGFBP-evasion mechanism [2]. Ross 1989 is the mechanistic key: IGFBPs suppressed IGF-1 and IGF-2 activity but not des(1-3)IGF-1, showing the derivative's potency comes from escaping IGFBP sequestration.
3. Anabolism in diabetic rats [3]. Tomas 1991 found that both IGF-1 and des(1-3)IGF-1 increased weight gain, nitrogen retention and muscle protein synthesis in diabetic rats, with lean-tissue-directed anabolism.
4. Anabolism in glucocorticoid-catabolic rats [4]. Tomas 1992 found the IGFBP-evading variants des(1-3)IGF-1 and LR3-IGF-1 were ~2.5x more potent than intact IGF-1 in dexamethasone-treated rats, despite weaker receptor binding.
5. Pituitary GH/IGFBP secretion in vitro [5]. Simes 1991 showed des(1-3)IGF-1 affected GH and IGFBP secretion from cultured rat anterior pituitary cells with greater potency than intact IGF-1.
6. Human evidence: essentially none. No controlled human efficacy or safety trials of IGF-1 DES exist. Claims of human body-composition or recovery benefit are extrapolations from rodent and cell data, not findings from human research.

How long does IGF-1 DES take to work?

There is no human timeline data for IGF-1 DES because there are no human trials. Any statement about how quickly effects appear in people would be speculation. What can be said is mechanistic and drawn from animals: free IGF peptides that escape IGFBP binding are understood to clear rapidly (minutes), so there is no carrier-driven sustained exposure.

No human onset-of-effect data exists for IGF-1 DES — no controlled trial has measured a timeline in people. In the rodent literature, anabolic effects (weight gain, nitrogen retention, muscle protein synthesis) were measured over multi-day continuous subcutaneous infusion, not from single injections, and those parameters describe animals rather than humans. Mechanistically, because des(1-3)IGF-1 escapes the IGFBP carrier system that prolongs intact IGF-1's half-life, free IGF peptides are expected to clear within minutes — there is no verified human pharmacokinetic profile to define a meaningful onset or duration.

How is IGF-1 DES dosed?

No validated human dosing protocol for IGF-1 DES exists. The only quantified doses in the published literature are animal (rodent subcutaneous mini-pump infusion, roughly 1–2 mg/kg/day in the Australian studies) and cell-culture nanomolar concentrations. Those are experimental parameters for animals and cells — not recommendations for humans. Any human 'research dose' circulating in community sources is not derived from published clinical evidence.

How is IGF-1 DES administered?

There is no established human administration protocol for IGF-1 DES. The route reported in the animal literature is subcutaneous, but timing, food-state, and steady-state parameters were never characterized for humans. The aspect table below reports only what is actually established (very little); the reconstitution table is illustrative unit-conversion math and NOT a recommended human dose.

What does IGF-1 DES stack well with?

In community discussion IGF-1 DES is often mentioned alongside GH secretagogues and other IGF-axis peptides, on the theory that stimulating endogenous GH raises IGF-1 while a locally-acting IGF variant adds direct receptor activation. This is a rationale, not evidence: there are no controlled human studies of any IGF-1 DES stack, so no synergy claim can be substantiated. The links below are to related profiles for orientation only.

1. IGF-1 LR3. IGF-1 LR3 is the other IGFBP-evading IGF-1 variant and the most common point of comparison. The two are alternative approaches to the same evasion goal — there is no evidence for combining them, and doing so would stack two IGF-1 receptor agonists with no human safety data.
2. GH secretagogues. IGF-1 DES is often discussed alongside Ipamorelin, CJC-1295, and MK-677, which raise endogenous GH and IGF-1. Any combined use is community practice, not a protocol supported by controlled human data.
3. No demonstrated synergy. No published study has tested IGF-1 DES in a human stack. Claims of additive or synergistic benefit are speculative and should be treated as such.

What are the side effects of IGF-1 DES?

The human safety profile of IGF-1 DES is unknown — there are no controlled human trials to characterize it. The concerns below are extrapolated from the biology of the IGF axis in general, not from data specific to des(1-3)IGF-1 in humans. They are theoretical risks, and their absence from a list does not mean an effect is safe.

Does IGF-1 DES interact with other drugs?

No human interaction studies of IGF-1 DES exist. The one interaction that is conceptually clear-cut is with agents affecting glucose control, because IGF-1 receptor activation has insulin-like effects. Everything else is unstudied.

1. Insulin and glucose-lowering agents. Because IGF-1 receptor activation lowers blood glucose, concurrent use with insulin or other hypoglycemic agents could theoretically compound hypoglycemia. This is a conceptual interaction, not one measured in humans for des(1-3)IGF-1.
2. Other IGF-1 receptor agonists (e.g., IGF-1 LR3, full-length IGF-1). Combining agonists at the same receptor stacks the same theoretical risks (hypoglycemia, tissue overgrowth) with no human data to bound them.
3. No characterized drug-drug pharmacokinetic interactions. There are no published human interaction studies of any kind for IGF-1 DES.

How should IGF-1 DES be stored?

1. Lyophilized (powder) form: Store at -20°C for long-term storage; refrigerate at 2–8°C for short-term.
2. Reconstituted solution: Store at 2–8°C; use within 28–30 days.
3. Reconstitute with bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
4. Never freeze reconstituted solution.
5. Protect from light. Store in original carton.
6. Discard if cloudy, discolored, or contains particles.

What are the limitations of IGF-1 DES research?

This is the most important section on the page. IGF-1 DES is a preclinical research compound with no human evidence base. Read the mechanism and potency claims elsewhere on this page through that lens: they come from rodents and cell dishes, not people.

Where to source IGF-1 DES

IGF-1 DES is not FDA-approved for any human use and is sold only as a research-grade peptide. It is a niche compound with limited vendor coverage. In PP's vetted directory it is currently listed by the vendor highlighted below, which publishes batch certificates of analysis.

IGF-1 DES FAQ

References

1. Ballard FJ, Francis GL, Ross M, Bagley CJ, May B, Wallace JC. Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding. Biochem Biophys Res Commun. 1987;149(2):398-404. https://pubmed.ncbi.nlm.nih.gov/2962574/
2. Ross M, Francis GL, Szabo L, Wallace JC, Ballard FJ. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J. 1989;258(1):267-272. https://pubmed.ncbi.nlm.nih.gov/2539101/
3. Tomas FM, Knowles SE, Owens PC, et al. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Biochem J. 1991;276(Pt 2):547-554. https://pubmed.ncbi.nlm.nih.gov/1710892/
4. Tomas FM, Knowles SE, Owens PC, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J. 1992;282(Pt 1):91-97. https://pubmed.ncbi.nlm.nih.gov/1371669/
5. Simes JM, Wallace JC, Walton PE. The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF analogue, on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells. J Endocrinol. 1991;130(1):93-99. https://pubmed.ncbi.nlm.nih.gov/1715381/

Published Studies